Nautilus Biotechnology Stock Investor Sentiment

NAUT Stock  USD 1.12  0.01  0.90%   
Slightly above 58% of Nautilus Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Nautilus Biotechnology suggests that many traders are alarmed. Nautilus Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Nautilus Biotechnology's earnings reports, geopolitical events, and overall market trends.
  

Nautilus Biotechnology Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Nautilus Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at globenewswire.com         
Nautilus Biotechnology Reports First Quarter 2024 Financial Results
Macroaxis News: globenewswire.com
over six months ago at gurufocus.com         
Nautilus Biotechnology Inc Q1 2024 Earnings Narrower Loss Than Expected
Gurufocus Stories at Macroaxis
over six months ago at news.google.com         
Nautilus Biotechnology Scheduled to Post Quarterly Earnings on Tuesday - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Disposition of 3647500 shares by Altman Michael Seth of Nautilus Biotechnology subject to Rule 16b-3
Yahoo News
over six months ago at finance.yahoo.com         
Jeff Bezos Earns So Much He Could Buy a Rolex Every Second How Does He Make Money?
Yahoo News
over six months ago at news.google.com         
Nautilus Biotechnology Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Acquisition by Mcilwain Matthew S of 13568 shares of Nautilus Biotechnology at 7.6849 subject to Rul...
Macroaxis News
over six months ago at www.macroaxis.com         
Acquisition by Subra Sankar of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3
Macroaxis News
over six months ago at globenewswire.com         
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
Macroaxis News: globenewswire.com
over six months ago at www.macroaxis.com         
Acquisition by Posard Matthew L. of 86467 shares of Nautilus Biotechnology at 2.7 subject to Rule 16...
Macroaxis News
over six months ago at simplywall.st         
Insiders of Nautilus Biotechnology, Inc. must be frustrated after market cap dropped US38m since rec...
Simply Wall St News at Macroaxis
over six months ago at news.google.com         
Trade Alert The Co-Founder Of Nautilus Biotechnology, Inc. , Sujal Patel, Has Just Spent US198k ... ...
Google News at Macroaxis
over six months ago at finance.yahoo.com         
If You Invested 4,500 in 9 Companies With Jeff Bezos, You Would Be Worth 7,316
Yahoo News
over a year ago at news.google.com         
Insider Buying Nautilus Biotechnology, Inc. CEO Acquires 34,204.96 in Stock - MarketBeat
Google News at Macroaxis
over a year ago at finance.yahoo.com         
Acquisition by Sujal Patel of 12044 shares of Nautilus Biotechnology at 2.8409 subject to Rule 16b-3
Yahoo News
Far too much social signal, news, headlines, and media speculation about Nautilus Biotechnology that are available to investors today. That information is available publicly through Nautilus media outlets and privately through word of mouth or via Nautilus internal channels. However, regardless of the origin, that massive amount of Nautilus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nautilus Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nautilus Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nautilus Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nautilus Biotechnology alpha.

Nautilus Biotechnology Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Nautilus Biotechnology Trading Down 5.9 percent - Heres Why - MarketBeat
02/12/2025
2
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results
02/27/2025
3
Nautilus Biotechnology Inc Q4 2024 Earnings Call Highlights Progress in Proteome ...
02/28/2025
4
Acquisition by Subra Sankar of 160000 shares of Nautilus Biotechnology at 1.24 subject to Rule 16b-3
03/03/2025
5
Acquisition by Nelson Nicholas A. of 160000 shares of Nautilus Biotechnology at 1.24 subject to Rule 16b-3
03/07/2025
6
Acquisition by Nazem Farzad of 45000 shares of Nautilus Biotechnology at 2.56 subject to Rule 16b-3
03/14/2025

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.